The S&P/ASX 200 Index (ASX: XJO) rose 0.9% last week in a positive start to the new financial year.
In FY26, ASX 200 shares put in a respectable performance, lifting 2.8% and delivering total returns of 7%.
Here, we look at three ASX 200 shares that the experts have a bullish view on for FY27.
Image source: Getty Images
Zip Co Ltd (ASX: ZIP)
The Zip share price rose 5.5% to close out FY26 at $3.24 on 30 June.
Jonathon Higgins from United Capital Partners (UCPS) has a buy rating on this ASX 200 buy now, pay later share for FY27.
Higgins considers Zip's turnaround over the past few years as one of the best he's ever witnessed.
In a new note, Higgins points out that Zip is on track to report annual cash earnings of more than $260 million just three years after a $50 million cash earnings loss.
Back then, Zip abandoned its plans for global expansion to instead focus on its core markets of Australia and the US.
Today, Higgins reckons the market is underappreciating Zip's cost discipline and its prospects for further growth in the US.
Compared to US-listed BNPL peers, Higgins says Zip shares are the cheapest and could be in for a re-rate in FY27.
UCPS has a buy rating on Zip with a target share price of $4.85. This implies a potential 50% upside over the next 12 months.
Higgins commented:
Sustainable earnings momentum against structural growth is hard to find on the ASX currently.
Resmed CDI (ASX: RMD)
The Resmed share price fell 26.6% to $28.88 on 30 June amid a broader healthcare sector downturn in FY26.
Blake Halligan from Catapult Wealth has a buy rating on this ASX 200 healthcare share.
Halligan explained (courtesy The Bull):
ResMed is a global leader in sleep apnoea devices and digital health platforms, benefiting from strong structural demand and resilient clinical positioning.
Despite the progression in GLP-1 therapies for treating sleep apnoea, ResMed's CPAP (continuous positive airway pressure) treatments remain superior at this point in time.
RMD continues to offer appealing growth, income and defensive healthcare exposure.
QBE Insurance Group Ltd (ASX: QBE)
The QBE share price lifted 7.7% in FY26 to close the year at $25.19.
In an article, fund manager Market Partners described QBE as one of the most compelling artificial intelligence (AI) cost-reduction stories on the ASX.
The QBE share price has been on a tear since the insurer reported a 21% increase in net profit after tax (NPAT) for FY25 in February.
QBE shares hit a multi-year high of $25.32 on the first day of the new financial year.
Gerrish explained their bullish view on the ASX 200 financial share in a recent webinar:
They've been working hard over the last five, 10 years around simplification of their business.
So they went out there, they made a huge number of acquisitions… and it's starting to pay benefits.
The experts said QBE was an emerging turnaround story, with the share price now trading at 15-year highs.
Gerrish added:
Turnarounds can take a lot longer than anyone envisages.
But once a turnaround is starting to gain traction like it is in QBE, then the stock can run a lot further and a lot longer than anyone thinks.
So, on 12x [P/E], growing earnings at high single digits, yielding 4.7% part-franked [dividends] with earnings tailwinds, we think QBE stacks up.
